Discounted Cash Flow Rating

Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Sell

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Aldeyra Therapeutics, Inc. (ALDX)

Pharmaceutical Preparations

https://www.aldeyra.com

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

131 HARTWELL AVENUE, SUITE 320
LEXINGTON, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/02/2014

Market Cap

299,484,864

Shares Outstanding

58,820,000

Weighted SO

58,822,083

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

TARS --.--%

LIAN --.--%

TVTX --.--%

ETON --.--%

VRDN --.--%

TERN --.--%

GPCR --.--%

BPMC --.--%

ETNB --.--%

Beta

1.4460

Last Div

0.0000

Range

1.42-7.81

Chg

-0.2100

Avg Vol

451524

Mkt Cap

299484864

Exch

NASDAQ

Country

US

Phone

781 761 4904

DCF Diff

2.9126

DCF

2.1574

Div Yield

0.0000

P/S

762.7856

EV Multiple

-6.9470

P/FV

3.0460

Div Yield %

0.0000

P/E

-7.9074

PEG

-0.2025

Payout

0.0000

Current Ratio

4.4135

Quick Ratio

4.4135

Cash Ratio

1.1245

DSO

37186.0832

DIO

0.0000

Op Cycle

37186.0832

DPO

366.0113

CCC

36820.0719

Gross Margin

0.3537

Op Margin

-109.6475

Pretax Margin

-96.4534

Net Margin

-96.4534

Eff Tax Rate

0.0313

ROA

-0.3004

ROE

-0.3333

ROCE

-0.4373

NI/EBT

1.0000

EBT/EBIT

0.8797

EBIT/Rev

-109.6475

Debt Ratio

0.1241

D/E

0.1590

LT Debt/Cap

0.0014

Total Debt/Cap

0.1372

Int Coverage

-40.0862

CF/Debt

-1.9648

Equity Multi

1.2821

Rec Turnover

0.0098

Pay Turnover

0.9972

Inv Turnover

0.0000

FA Turnover

0.9957

Asset Turnover

0.0031

OCF/Share

-0.5171

FCF/Share

-0.5171

Cash/Share

1.3521

OCF/Sales

-78.2473

FCF/OCF

1.0000

CF Coverage

-1.9648

ST Coverage

-1.9824

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

3.0460

P/B

3.0460

P/S

762.7856

P/E

-7.9074

P/FCF

-9.7484

P/OCF

-9.7472

P/CF

-9.7472

PEG

-0.2025

P/S

762.7856

EV Multiple

-6.9470

P/FV

3.0460

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 15, 01:00 Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm GlobeNewswire Inc. Apr 29, 01:00 Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm GlobeNewswire Inc. Apr 22, 01:00 Bragar Eagel & Squire, P.C. Is Investigating TechTarget and Aldeyra and Encourages Investors to Contact the Firm GlobeNewswire Inc. Apr 09, 21:00 Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA’s Reproxalap Complete Response Letter – Hagens Berman PennyStocks Nov 07, 14:12 Invest In Penny Stocks? Is It Worth It & 4 To Watch Now PennyStocks Nov 01, 14:11 5 Most Active Penny Stocks Today & Why They’re Moving Now

Revenue Product Segmentation